특발성 혈소판 감소성 자반증(ITP) 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market size is expected to reach USD 1215.71 Million in 2034 from USD 741.95 Million (2025) growing at a CAGR of 5.64% during 2026-2034.

The Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is growing as awareness and diagnosis of autoimmune blood disorders continue to increase worldwide. ITP is a condition characterized by low platelet counts, which can lead to excessive bruising and bleeding. Advances in diagnostic technologies and improved healthcare infrastructure are helping physicians identify the disease more effectively, thereby increasing demand for effective treatment options.

Several factors are driving the growth of the ITP therapeutics market, including the development of innovative treatment approaches and targeted therapies. Pharmaceutical companies are investing heavily in research and development to create more effective drugs with fewer side effects. Additionally, the increasing adoption of biologics and immunotherapies is improving treatment outcomes for patients with chronic ITP.

In the future, the market is expected to expand further due to growing investments in rare disease research and advancements in biotechnology. The introduction of novel therapeutic agents and improved patient management strategies will likely enhance treatment accessibility. Moreover, supportive government initiatives and rising healthcare spending in emerging economies will contribute to the long-term growth of the ITP therapeutics market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Acute thrombocytopenic purpura
• Chronic thrombocytopenic purpura

By Product

• Corticosteroids
• Intravenous immunoglobulins (IVIG)
• Thrombopoietin receptor agonists (TPO-RA)
• Other products

By Route of Administration

• Oral
• Injectable

By Age Group

• Pediatric
• Adult
• Geriatric

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

COMPANIES PROFILED

• Amgen, CSL Behring, F Hoffmann La Roche, GlaxoSmithKline, Grifols, Intas Pharmaceuticals, Kedrion Biopharma, Novartis, Octapharma AG, Sobi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Acute thrombocytopenic purpura Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chronic thrombocytopenic purpura Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous immunoglobulins (IVIG) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Thrombopoietin receptor agonists (TPO-RA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Product
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Age Group
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Product
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Age Group
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Product
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Age Group
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Product
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Age Group
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Product
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Age Group
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Amgen
  • 11.2.2 CSL Behring
  • 11.2.3 F. Hoffmann La Roche
  • 11.2.4 GlaxoSmithKline
  • 11.2.5 Grifols
  • 11.2.6 Intas Pharmaceuticals
  • 11.2.7 Kedrion Biopharma
  • 11.2.8 Novartis
  • 11.2.9 Octapharma AG
  • 11.2.10 Sobi